Yimin Wu

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51
    Yimin Wu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, United States of America
    PLoS ONE 3:e2636. 2008
  2. pmc Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex
    Yimin Wu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Proc Natl Acad Sci U S A 103:18243-8. 2006
  3. pmc Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders
    Feng Qian
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 26:2521-7. 2008
  4. pmc Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria
    Ruth D Ellis
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIAID NIH, Rockville, Maryland, United States of America
    PLoS ONE 7:e46094. 2012
  5. pmc Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates
    Feng Qian
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 25:3923-33. 2007
  6. pmc Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure
    Feng Qian
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Microbes Infect 11:408-12. 2009
  7. pmc Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine
    Daming Zhu
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 29:3640-5. 2011
  8. pmc The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species
    Lediya Cheru
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 28:4423-9. 2010
  9. pmc A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates
    Joanna Kubler-Kielb
    Program on Developmental and Molecular Immunity, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:1172-7. 2010
  10. pmc Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate
    Matthew L Plassmeyer
    Malaria Vaccine Development Branch, NIAID, National Institutes of Health, Rockville, Maryland 20852, USA
    J Biol Chem 284:26951-63. 2009

Collaborators

Detail Information

Publications25

  1. pmc Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51
    Yimin Wu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, United States of America
    PLoS ONE 3:e2636. 2008
    ..This single blinded, dose escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51, a water-in-oil emulsion...
  2. pmc Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex
    Yimin Wu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Proc Natl Acad Sci U S A 103:18243-8. 2006
    ..Protein antigen conjugation to OMPC or other protein carrier may have general application to a spectrum of protein subunit vaccines to increase immunogenicity without the need for potentially reactogenic adjuvants...
  3. pmc Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders
    Feng Qian
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 26:2521-7. 2008
    ..The results obtained in this study indicate the potential use of a combination strategy to increase the number of responders to malarial antigens in humans...
  4. pmc Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria
    Ruth D Ellis
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIAID NIH, Rockville, Maryland, United States of America
    PLoS ONE 7:e46094. 2012
    ..In vitro growth inhibition was demonstrated and was closely correlated with anti-AMA1 antibody responses. A Phase 1b trial in malaria-exposed adults is being conducted. Trial registration: Clinicaltrials.gov NCT00889616...
  5. pmc Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates
    Feng Qian
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 25:3923-33. 2007
    ..These conjugates now need to be tested in humans to determine if mice are predictive of the response in humans...
  6. pmc Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure
    Feng Qian
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Microbes Infect 11:408-12. 2009
    ..A significant increase in immunogenicity measured by ELISA was observed in mice immunized with conjugated Pfs28 as compared to unconjugated Pfs28...
  7. pmc Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine
    Daming Zhu
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 29:3640-5. 2011
    ..The results of the present study indicate that the AMA1-C1/ISA 720 emulsion was unstable after 12 months of storage, after which AMA1-C1 proteins were partially degraded...
  8. pmc The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species
    Lediya Cheru
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 28:4423-9. 2010
    ..These data suggests that information obtained from animal studies which assess efficacy of TBV candidates may be difficult to translate to human immunization...
  9. pmc A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates
    Joanna Kubler-Kielb
    Program on Developmental and Molecular Immunity, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:1172-7. 2010
    ....
  10. pmc Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate
    Matthew L Plassmeyer
    Malaria Vaccine Development Branch, NIAID, National Institutes of Health, Rockville, Maryland 20852, USA
    J Biol Chem 284:26951-63. 2009
    ..5 nm in width. Thus native CSP appears as a glycosylphosphatidylinositol-anchored, flexible rod-like protein on the sporozoite surface...
  11. ncbi request reprint Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria
    Elissa M Malkin
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook 1, Room 1123, Rockville, MD 20852, USA
    Vaccine 23:3131-8. 2005
    ..Pvs25H generates transmission blocking immunity in humans against P. vivax demonstrating the potential of this antigen as a component of a transmission blocking vaccine...
  12. pmc Determination of protein concentration for protein-protein conjugates using ultraviolet absorption
    Daming Zhu
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    J Immunol Methods 387:317-21. 2013
    ..The accuracy of the method was verified using mixtures of known proteins. The present study provides a rapid, simple and accurate method for determining protein concentration in protein-protein conjugates...
  13. pmc Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25
    Joanna Kubler-Kielb
    Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, 31 Center Drive, MSC 2423, Bethesda, MD 20892 2520, USA
    Proc Natl Acad Sci U S A 104:293-8. 2007
    ..The observed transmission-blocking activity of immune sera correlated with antibody levels measured by ELISA...
  14. pmc Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle
    Richard L Shimp
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 31:2954-62. 2013
    ..A phase 1 human trial using the Pfs25-EPA/Alhydrogel(®) formulation is ongoing in the United States...
  15. pmc A class of tricyclic compounds blocking malaria parasite oocyst development and transmission
    Richard T Eastman
    Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Antimicrob Agents Chemother 57:425-35. 2013
    ..Further clinical evaluation of ketotifen and related compounds, including synthetic new derivatives, in blocking malaria transmission may provide new weapons for the current effort of malaria eradication...
  16. ncbi request reprint Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations
    Aaron P Miles
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook I Room 1118, Rockville, MD 20852, USA
    Vaccine 23:2530-9. 2005
    ....
  17. pmc Blood stage vaccines for Plasmodium falciparum: current status and the way forward
    Ruth D Ellis
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
    Hum Vaccin 6:627-34. 2010
    ..Alternative preclinical and clinical development paths will speed iterative development...
  18. pmc Plasmodium p25 and p28 surface proteins: potential transmission-blocking vaccines
    Ajay K Saxena
    School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India
    Eukaryot Cell 6:1260-5. 2007
  19. ncbi request reprint The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials
    Souraya Ramjanee
    Division of Cell and Molecular Biology, Sir Alexander Fleming Building, Imperial College London, Imperial College Road, London SW7 2AZ, UK
    Vaccine 25:886-94. 2007
    ..To this end the cloned lines have been deposited with, and are freely available from, MR4...
  20. pmc Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum
    Takeshi Arakawa
    Division of Molecular Microbiology, Center for Molecular Biosciences, University of Ryukyus, Nishihara, Okinawa, Japan
    Infect Immun 73:7375-80. 2005
    ....
  21. ncbi request reprint Isolation and functional characterization of a dynamin-like gene from Plasmodium falciparum
    HuiLiang Li
    Department of Etiology, Molecular Parasitology Laboratory, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China
    Biochem Biophys Res Commun 320:664-71. 2004
    ..falciparum parasite at the erythrocyte stage. Those data showed that Pfdyn1 is a conservative, membrane related protein and plays an essential role for the survival of Plasmodium parasite...
  22. pmc Data-mining approaches reveal hidden families of proteases in the genome of malaria parasite
    Yimin Wu
    Department of Protistology, American Type Culture Collection, Manassas, Virginia 20110, USA
    Genome Res 13:601-16. 2003
    ..The present study represents an initial effort to identify a set of expressed, active, and essential proteases as targets for inhibitor-based drug design...
  23. ncbi request reprint A proteomic view of the Plasmodium falciparum life cycle
    Laurence Florens
    Department of Cell Biology, The Scripps Research Institute, SR 11, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
    Nature 419:520-6. 2002
    ..The detection of chromosomal clusters encoding co-expressed proteins suggested a potential mechanism for controlling gene expression...
  24. ncbi request reprint Early inflammatory response in rat brain after peripheral thermal injury
    Raul Reyes
    Department of Neurosurgery, The University of Texas Health Science Center at San Antonio, Mail Code 7843, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, United States
    Neurosci Lett 407:11-5. 2006
    ..This study demonstrated an early inflammatory response in the brain after severe peripheral thermal injury. The cerebral inflammatory reaction was associated with expression of systemic cytokines and an adhesion molecule...
  25. ncbi request reprint Computer assisted searches for drug targets with emphasis on malarial proteases and their inhibitors
    Yufeng Wang
    Department of Biology, University of Texas at San Antonio, 6900 North Loop 1604 West, San Antonio, Texas 78249, USA
    Curr Drug Targets Infect Disord 4:25-40. 2004
    ..As a case study, we look at the identification and investigation of malarial proteases as therapeutic targets in the Plasmodium spp. parasites...